The firm closed an oversubscribed Series B financing round to fund a pivotal trial of RTx-015 and advance a clinical trial in ...

Regulators reviewed data from the Phase II FIREFLY-1 trial, in which the overall response rate was 53 percent, according to a scale for low-grade gliomas.

NEW YORK – A single dose of Kyverna Therapeutics' experimental CAR T-cell therapy improved mobility for patients with a rare ...

SAN DIEGO – Nuvation's Ibtrozi (taletrectinib) is yielding high response rates in patients with metastatic non-small cell ...

SAN DIEGO – While oncologists may not yet be entirely comfortable using next-generation artificial intelligence tools to ...

All 20 patients who received the CAR-T in the Phase II study were MRD negative at the data cutoff, but some also had ...

Two studies presented at the meeting showed the potential of D3 Bio's next-gen KRAS (OFF) inhibitor and Revolution Medicine's ...

The organizations are betting they can develop a redosable genetic therapy for LMNA-related congenital muscular dystrophy that could be a cure.

The institute said the NHS should make this combo available to patients after weighing its safety and efficacy against Tafinlar and Mekinist, the current standard treatment.

Some CLDN6-negative patients responded to the therapy, suggesting it had biomarker-agnostic potential, though the study ...

The institute backed the treatment after seeing that biliary tract cancer patients on Ziihera lived for an average 18 months, much longer than those on standard chemo can expect.

While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...